Format
Sort by
Items per page

Send to

Choose Destination

Best matches for liver failure AND ("QT" OR Torsad*):

Cirrhotic cardiomyopathy: Implications for liver transplantation. Liu H et al. Liver Transpl. (2017)

Drug-induced liver injury: Towards early prediction and risk stratification. Raschi E et al. World J Hepatol. (2017)

Cirrhotic cardiomyopathy. Ruiz-del-Árbol L et al. World J Gastroenterol. (2015)

Search results

Items: 1 to 20 of 68

1.

Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.

Uemura H, Tsukada K, Mizushima D, Aoki T, Watanabe K, Kinai E, Teruya K, Gatanaga H, Kikuchi Y, Sugiyama M, Mizokami M, Oka S.

PLoS One. 2017 Oct 18;12(10):e0186255. doi: 10.1371/journal.pone.0186255. eCollection 2017.

2.

Cirrhotic cardiomyopathy: Implications for liver transplantation.

Liu H, Jayakumar S, Traboulsi M, Lee SS.

Liver Transpl. 2017 Jun;23(6):826-835. doi: 10.1002/lt.24768. Review.

3.

Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case-Control Study.

Juba KM, Khadem TM, Hutchinson DJ, Brown JE.

J Palliat Med. 2017 Jul;20(7):722-728. doi: 10.1089/jpm.2016.0411. Epub 2017 Feb 10.

PMID:
28186837
4.

Drug-induced liver injury: Towards early prediction and risk stratification.

Raschi E, De Ponti F.

World J Hepatol. 2017 Jan 8;9(1):30-37. doi: 10.4254/wjh.v9.i1.30. Review.

5.

Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease.

Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, Kudo M.

Oncology. 2017;92 Suppl 1:3-9. doi: 10.1159/000451010. Epub 2016 Dec 15.

6.

Propionic Acidemia.

Shchelochkov OA, Carrillo N, Venditti C.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
2012 May 17 [updated 2016 Oct 6].

7.

[Cardiac damage in liver cirrhosis in alcohol abusers].

Romanova VA, Goncharov AS, Terebilina NN, Moiseev VS.

Ter Arkh. 2016;88(8):99-104. doi: 10.17116/terarkh201688899-104. Russian.

PMID:
27636934
8.

[Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].

Hunyady B, Abonyi M, Csefkó K, Gervain J, Haragh A, Horváth G, Jancsik V, Makkai E, Müller Z, Ribiczey P, Sipos B, Szabó O, Szalay F, Szentgyörgyi L, Tornai I, Újhelyi E, Varga M, Weisz G, Makara M.

Orv Hetil. 2016 Aug;157(34):1366-74. doi: 10.1556/650.2016.30538. Hungarian.

PMID:
27546804
9.

Changes of QT Dispersion in Hemodialysis Patients after Administrating Zhigancao Decoction ().

Tong YQ, Sun M, Hu CJ, Zhao DK.

Chin J Integr Med. 2018 Aug;24(8):627-631. doi: 10.1007/s11655-016-2599-6. Epub 2016 Jul 19.

PMID:
27435290
10.

Impact and persistence of cirrhotic cardiomyopathy after liver transplantation.

Sonny A, Ibrahim A, Schuster A, Jaber WA, Cywinski JB.

Clin Transplant. 2016 Sep;30(9):986-93. doi: 10.1111/ctr.12778. Epub 2016 Jul 8.

PMID:
27292629
11.

Diastolic Dysfunction in Liver Cirrhosis: Prognostic Predictor in Liver Transplantation?

Carvalheiro F, Rodrigues C, Adrego T, Viana J, Vieira H, Seco C, Pereira L, Pinto F, Eufrásio A, Bento C, Furtado E.

Transplant Proc. 2016 Jan-Feb;48(1):128-31. doi: 10.1016/j.transproceed.2016.01.010.

PMID:
26915857
12.

Cirrhotic cardiomyopathy.

Ruiz-del-Árbol L, Serradilla R.

World J Gastroenterol. 2015 Nov 7;21(41):11502-21. doi: 10.3748/wjg.v21.i41.11502. Review.

13.

Systemic vascular resistance and fluid status in patients with decompensated liver cirrhosis with or without functional renal failure in Egypt.

Barakat AA, Nasr FM, Metwaly AA, El-Ghannam M.

Electron Physician. 2015 Aug 10;7(4):1174-82. doi: 10.14661/2015.1174-1182. eCollection 2015 Aug.

14.

QTc interval prolongation and hepatic encephalopathy in patients candidates for liver transplantation: A valid inference?

Marafioti V, Benetti V, Montin U, Carbone V, Petrosino A, Tedeschi U, Rossi A.

Int J Cardiol. 2015 Jun 1;188:43-4. doi: 10.1016/j.ijcard.2015.04.026. Epub 2015 Apr 6. No abstract available.

PMID:
25885747
15.

Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Rahman S, Mallett SV.

World J Hepatol. 2015 Mar 27;7(3):507-20. doi: 10.4254/wjh.v7.i3.507. Review.

16.

QT interval prolongation associated with amiodarone use in Cipto Mangunkusumo Hospital, Jakarta.

Nafrialdi, Kurniawan TG, Setiawati A, Makmun LH.

Acta Med Indones. 2014 Oct;46(4):292-7.

17.

[DIAGNOSIS AND CLINICAL MANIFESTATIONS OF CIRRHOTIC CARDIOMYOPATHY].

Rodina AS, Shubina ME, Dudanova OP.

Eksp Klin Gastroenterol. 2015;(11):34-7. Russian.

PMID:
27214985
18.

Cirrhotic cardiomyopathy: a cardiologist's perspective.

Gassanov N, Caglayan E, Semmo N, Massenkeil G, Er F.

World J Gastroenterol. 2014 Nov 14;20(42):15492-8. doi: 10.3748/wjg.v20.i42.15492. Review.

19.

Cirrhotic cardiomyopathy: review of pathophysiology and treatment.

Chayanupatkul M, Liangpunsakul S.

Hepatol Int. 2014 Jul;8(3):308-15. doi: 10.1007/s12072-014-9531-y.

20.

QT interval prolongation in end-stage liver disease cannot be explained by nonhepatic factors.

Patel D, Singh P, Katz W, Hughes C, Chopra K, Němec J.

Ann Noninvasive Electrocardiol. 2014 Nov;19(6):574-81. doi: 10.1111/anec.12161. Epub 2014 Apr 24.

PMID:
24762117

Supplemental Content

Loading ...
Support Center